News

How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across

For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and

For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and

For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and

How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compare investment results across sectors

Twist Bioscience (TWST) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.79 per share a year ago. These figures

The three most widely followed indexes in the United States have ended the past trading week on a positive note. The Nasdaq Composite, the S&P 500 and the Dow Jones Industrial Average have gained by

The S&P 500 Index has been able to recoup all losses suffered due to the Trump administration’s tariff-led market mayhem at a lightning speed. On May 2, the broad-market index recorded a nine-day

Wall Street saw severe volatility and almost day-to-day fluctuations in both directions in April. Finally, U.S. stock markets ended mixed last month. The S&P 500 and the Dow fell 3.2% and 0.8%

An updated edition of the March 12, 2025, article.

In the business world, the concept of a wide moat refers to companies with strong, durable competitive advantages that protect them from rivals

BioCryst Pharmaceuticals (BCRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.17 per share a year ago. These

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:

GeneDx Holdings Corp. WGS: This genomics-related diagnostic and information services company has seen the Zacks Consensus

It is not surprising that before an earnings season, every investor looks for stocks that can beat market expectations. This is because investors always try to position themselves ahead of time and

Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.09 per share a year ago. These

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.24 per share a year ago. These figures

Flex Ltd. FLEX is scheduled to report fourth-quarter fiscal 2025 results on May 7, before the market opens.

The Zacks Consensus Estimate for fiscal fourth-quarter revenues is pegged at $6.23

IRadimed (IRMD) came out with quarterly earnings of $0.42 per share, missing the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.36 per share a year ago. These figures

TG Therapeutics (TGTX) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to loss of $0.07 per share a year ago. These

Angel Oak Mortgage (AOMR) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.11 per share a year ago. These

For Immediate Release

Chicago, IL – May 5, 2025 – Zacks.com releases the list of companies likely to issue earnings surprises. This week’s list includes Microsoft MSFT, Meta Platforms META, Amazon A

As a global financial services firm specializing in brokerage and financial technology, BGC Group Inc. BGC is at the forefront of digital transformation in capital markets. The company is slated to

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for earnings, it missed the same for sales. Earnings of 92 cents per share rose